Human Pathology
Volume 41, Issue 9 , Pages 1299-1309 , September 2010

Clonal analysis of bilateral, recurrent, and metastatic papillary thyroid carcinomas

  • Weibin Wang, MD

      Affiliations

    • Cancer Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
    • ,
  • Haiyong Wang, MD

      Affiliations

    • Cancer Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
    • ,
  • Xiaodong Teng, MD

      Affiliations

    • Department of Pathology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
    • ,
  • Haohao Wang, MD

      Affiliations

    • Cancer Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
    • ,
  • Chenyu Mao, MD

      Affiliations

    • Cancer Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
    • ,
  • Rongyue Teng, MD

      Affiliations

    • Cancer Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
    • ,
  • Wenhe Zhao, MD

      Affiliations

    • Cancer Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
    • ,
  • Jiang Cao, PhD

      Affiliations

    • Key Laboratory of Biotherapy of Zhejiang Province, Sir Run Run Shaw Institute of Clinical Medicine, Zhejiang University, Hangzhou 310016, China
    • ,
  • Thomas J. Fahey III, MD

      Affiliations

    • Department of Surgery, New York Presbyterian Hospital, and Weill Medical College of Cornell University, New York, NY 10021, USA
    • ,
  • Lisong Teng, MD, PhD

      Affiliations

    • Cancer Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
    • Corresponding Author InformationCorresponding author.

Received 26 November 2009 ,Revised 9 February 2010 ,Accepted 25 February 2010.

References 

  1. Franceschi S, Boyle P, Maisonneuve P, et al. The epidemiology of thyroid carcinoma. Crit Rev Oncog. 1993;4:25–52
  2. Tsang RW, Brierley JD, Simpson WJ, et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer. 1998;82:375–388
  3. Fernandes JK, Day TA, Richardson MS, et al. Overview of the management of differentiated thyroid cancer. Curr Treat Options Oncol. 2005;6:47–57
  4. Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375–381
  5. Pasieka JL, Thompson NW, McLeod MK, et al. The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy. World J Surg. 1992;16:711–716
  6. Pacini F, Elisei R, Capezzone M, et al. Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. Thyroid. 2001;11:877–881
  7. Katoh R, Sasaki J, Kurihara H, et al. Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients. Cancer. 1992;70:1585–1590
  8. Iida F, Yonekura M, Miyakawa M. Study of intraglandular dissemination of thyroid cancer. Cancer. 1969;24:764–771
  9. McCarthy RP, Wang M, Jones TD, et al. Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas. Clin Cancer Res. 2006;12:2414–2418
  10. Jovanovic L, Delahunt B, McIver B, et al. Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone. Pathol. 2008;215:145–154
  11. Shattuck TM, Westra WH, Ladenson PW, et al. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med. 2005;352:2406–2412
  12. Giannini R, Ugolini C, Lupi C, et al. The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:3511–3516
  13. Park SY, Park YJ, Lee YJ, et al. Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer. 2006;107:1831–1838
  14. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn. 2008;8:83–95
  15. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454–1457
  16. Hara H, Fulton N, Yashiro T, et al. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery. 1994;116:1010–1016
  17. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990;60:557–563
  18. Pierotti MA, Vigneri P, Bongarzone I. Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas. Recent Results Cancer Res. 1998;154:237–247
  19. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12:245–262
  20. Namba H, Matsuo K, Fagin JA. Clonal composition of benign and malignant human thyroid tumors. J Clin Invest. 1990;86:120–125
  21. Lyon MF. Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature. 1961;190:372–373
  22. DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol. 2006;94:662–669
  23. In:  Greene FL,  Page DL,  Fleming ID, et al. editor. American Joint Committee on Cancer staging manual. 6th ed.. Philadelphia: Springer; 2002;p. 77–87
  24. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954
  25. Tilley WD, Marcelli M, Wilson JD, et al. Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci U S A. 1989;86:327–331
  26. Allen RC, Zoghbi HY, Moseley AB, et al. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet. 1992;51:1229–1239
  27. Moniz S, Catarino AL, Marques AR, et al. Clonal origin of non-medullary thyroid tumours assessed by non-random X-chromosome inactivation. Eur J Endocrinol. 2002;146:27–33
  28. Carta C, Moretti S, Passeri L, et al. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clin Endocrinol (Oxf). 2006;64:105–109
  29. Jovanovic L, Delahunt B, McIver B, et al. Thyroid gland clonality revisited: the embryonal patch size of the normal human thyroid gland is very large, suggesting X-chromosome inactivation tumor clonality studies of thyroid tumors have to be interpreted with caution. J Clin Endocrinol Metab. 2003;88:3284–3291
  30. Carcangiu ML, Zampi G, Pupi A, et al. Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer. 1985;55:805–828
  31. Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005;65:4238–4245
  32. Trovisco V, Soares P, Preto A, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch. 2005;446:589–595
  33. Sedliarou I, Saenko V, Lantsov D, et al. The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol. 2004;25:1729–1735
  34. Reinhoff WF. Lymphatic vessels of thyroid gland in dog and man. Arch Surg. 1931;23:783–804
  35. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009;69:4885–4893

☆ Funding support: This study was supported by National Basic Research Program of China (973 Program, No. 2009CB521704) from the Ministry of Science and Technology of the People's Republic of China (Beijing, China).

PII: S0046-8177(10)00086-9

doi: 10.1016/j.humpath.2010.02.008

Human Pathology
Volume 41, Issue 9 , Pages 1299-1309 , September 2010

Article Tools

* Image Usage & Resolution